The FDA has approved a daily Wegovy pill, a new version of the weight loss drug. Novo Nordisk’s stock could see a strong comeback due to this approval. Shares have fallen by 40% in 2025 due to competition, but the pill’s approval may reinvigorate the company’s growth. Wegovy will hit the market next month.

Novo Nordisk shares rose following FDA approval of Wegovy. The pill, a form of Ozempic, showed significant weight loss in trials. It will be the first oral GLP-1 drug available. The new pill will help Novo Nordisk compete against rivals and drive growth. Wegovy will launch in early January.

Novo Nordisk continues to grow despite recent challenges. The stock’s low valuation presents a buying opportunity. The Wegovy pill’s potential success could lead to significant growth for the company. Investors should consider adding Novo Nordisk to their portfolio for potential market-beating returns in 2026.

The Motley Fool Stock Advisor team recommends 10 other stocks over Novo Nordisk for potential high returns. Novo Nordisk’s recent struggles may present a buying opportunity. Consider the potential for growth and dividends when evaluating Novo Nordisk as an investment in 2026.

Read more at Yahoo Finance: Should You Invest in Ozempic Maker Novo Nordisk in 2026?